Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENSEMBLE-2 total neoadjuvant therapy for locally advanced rectal cancer
jRCTs071210143Phase 2Active, not recruiting
- Start
- May 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and oxaliplatin in rectal cancer and rectal adenocarcinoma. Primary endpoint: Pathological complete response. Started May 2022; status: active, not recruiting.
02
Drugs
capecitabineoxaliplatin
03
Conditions
rectal cancerrectal adenocarcinoma
Beyond the preview
Go deeper on jRCTs071210143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071210143.